Literature DB >> 22155418

ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer.

Aaron H Wolfson1, Mahesh A Varia, David Moore, Gautam G Rao, David K Gaffney, Beth A Erickson-Wittmann, Anuja Jhingran, Nina A Mayr, Ajmel A Puthawala, William Small, Catheryn M Yashar, William Yuh, Higinia Rosa Cardenes.   

Abstract

OBJECTIVE: The use of adjuvant treatment(s) following initial hysterectomy and retroperitoneal nodal harvesting of patients with clinical stage I and II cervical carcinoma is (are) presently based on the pathological assessment of surgical specimens. This report sought to delineate further the clinical application of potential therapeutic interventions and associated follow-up investigations of this patient cohort.
METHODS: The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journal and the application of a well-established consensus methodology (modified Delphi) to rate appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
RESULTS: From this process, 5 unique clinical variants were developed. These scenarios pertained to options of adjuvant radiation therapy and chemotherapy, methods of delivery of radiotherapy to optimize target volume coverage while simultaneously minimizing radiation exposure of adjacent healthy organs, and recommendations for patient follow-up care. Group members reached consensus of topic ratings in descending order of importance. A risk assessment breakdown was established to highlight the most likely indications for adjuvant treatment(s).
CONCLUSION: This assembly by the ACR of physicians involved in the management of patients with early stage cervical cancer was able to describe appropriateness criteria to aid other practitioners in selecting reasonable implementation of postoperative therapies and subsequent surveillance studies. These guidelines await further validation and refinement by both current and future prospectively randomized clinical studies regarding this patient population. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22155418     DOI: 10.1016/j.ygyno.2011.11.048

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Bevacizumab in advanced cervical cancer.

Authors:  P J Vlachostergios; C N Papandreou
Journal:  Clin Transl Oncol       Date:  2014-09-03       Impact factor: 3.405

2.  Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy.

Authors:  John M Stahl; Jack M Qian; Christopher J Tien; David J Carlson; Zhe Chen; Elena S Ratner; Henry S Park; Shari Damast
Journal:  Support Care Cancer       Date:  2018-09-05       Impact factor: 3.603

3.  Correlation between clinical findings and magnetic resonance imaging for the assessment of local response after standard treatment in cervical cancer.

Authors:  Izaskun Valduvieco; Albert Biete; Iván Rios; Ricardo Llorente; Angels Rovirosa; Jaume Pahisa; Laura Vidal; Blanca Farrús; Pilar Samper
Journal:  Rep Pract Oncol Radiother       Date:  2013-06-18

4.  Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.

Authors:  Nicolò Bizzarri; Luigi Pedone Anchora; Gian Franco Zannoni; Vittoria Carbone; Matteo Bruno; Camilla Fedele; Valerio Gallotta; Vito Chiantera; Giacomo Avesani; Benedetta Gui; Francesco Fanfani; Anna Fagotti; Giovanni Scambia; Gabriella Ferrandina
Journal:  Br J Cancer       Date:  2021-04-14       Impact factor: 7.640

Review 5.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Frederico S Falcetta; Lídia Rf Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein; Daniela D Rosa
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

6.  Lymph node ratio may predict the benefit of postoperative radiotherapy in node-positive cervical cancer.

Authors:  Juan Zhou; Qiong-Hua Chen; San-Gang Wu; Zhen-Yu He; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Ke-Li You
Journal:  Oncotarget       Date:  2016-05-17

7.  Incorporation of the number of positive lymph nodes leads to better prognostic discrimination of node-positive early stage cervical cancer.

Authors:  Juan Zhou; San-Gang Wu; Jia-Yuan Sun; Xu-Lin Liao; Feng-Yan Li; Huan-Xin Lin; Li-Chao Yang; Zhen-Yu He
Journal:  Oncotarget       Date:  2017-04-18

8.  A nurse- and peer-led support program to assist women in gynaecological oncology receiving curative radiotherapy, the PeNTAGOn study (peer and nurse support trial to assist women in gynaecological oncology): study protocol for a randomised controlled trial.

Authors:  Penelope Schofield; Ilona Juraskova; Rebecca Bergin; Karla Gough; Linda Mileshkin; Meinir Krishnasamy; Kate White; David Bernshaw; Sylvia Penberthy; Sanchia Aranda
Journal:  Trials       Date:  2013-02-11       Impact factor: 2.279

9.  Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial.

Authors:  Lorraine M Elit; Anthony W Fyles; Chu-Shu Gu; Gregory R Pond; David D'Souza; Rajiv Samant; Margaret Anthes; Gillian Thomas; Marc Filion; Julie Arsenault; Ian Dayes; Timothy J Whelan; Karen Y Gulenchyn; Ur Metser; Kavita Dhamanaskar; Mark N Levine
Journal:  JAMA Netw Open       Date:  2018-09-07

10.  Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy.

Authors:  Dan Li; Xiaoxian Xu; Dingding Yan; Shuhui Yuan; Juan Ni; Hanmei Lou
Journal:  J Int Med Res       Date:  2019-12-31       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.